Phase II
Vera Therapeutics’ stock crashed following the reveal of data from a Phase IIb study of atacicept in IgAN.
Chemomab’s experimental antibody shows promise in NASH.
Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.
Jazz Pharmaceuticals exercised its option on Zymeworks’ promising anti-cancer agent.
Psychedelic and psychedelic-assisted therapies in the neuropsychiatric space have stalled for decades.
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.
Vertex is kicking off a Phase I trial assessing VX-522, an mRNA therapy designed to treat the underlying cause of cystic fibrosis lung disease, while SpliSense is targeting a specific mutation.
Shares of Avidity Biosciences are soaring following reported early signs of clinical activity and improvement in patients with myotonic dystrophy type 1 (DM1) treated with its RNA-based therapeutic.
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
Seagen’s top-selling drug hit the mark in another major indication.
PRESS RELEASES